Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 01 2021 - 07:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of March 2021
Commission
File Number 001-38370
CollPlant
Biotechnologies Ltd.
(Exact
name of registrant as specified in its charter)
4
Oppenheimer St, Weizmann Science Park
Rehovot
7670104, Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This
Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No.
333-229163 and 333-248479) and Form F-3 (File No. 333-229486, 333-228054 and 333-238731), to be a part thereof from the date on
which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
As
previously disclosed, on February 5, 2021, CollPlant Ltd. (“CollPlant”), a wholly-owned subsidiary of CollPlant Biotechnologies
Ltd. (the “Company”), entered into a Development, Exclusivity and Option Products Agreement (the “Agreement”)
with certain wholly-owned subsidiaries of AbbVie Inc. (collectively, “AbbVie”), pursuant to which CollPlant and AbbVie
will collaborate in the development and commercialization of dermal and soft tissue filler products for the medical aesthetics
market, using CollPlant’s recombinant human collagen (rhCollagen) technology. In accordance with the Agreement, on February
28, 2021, the Company received the $14.0 million upfront cash payment.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD.
|
|
|
|
Date: March 1, 2021
|
By:
|
/s/
Eran Rotem
|
|
|
Name:
|
Eran Rotem
|
|
|
Title:
|
Deputy CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Mar 2023 to Mar 2024